Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "U.S. Senate"

U.S. Senators Tell Drug Company Execs Pricing Is Morally Repugnant

Yasmeen Abutaleb & Michael Erman  |  February 28, 2019

WASHINGTON/NEW YORK (Reuters)—U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines. Executives from Abbvie Inc., AstraZeneca PLC., Sanofi SA, Pfizer…

U.S. Senate Finance Committee Invites Pharma Execs to Testify

Reuters Staff  |  February 5, 2019

WASHINGTON (Reuters)—A powerful U.S. Senate committee on has invited seven pharmaceutical companies to testify at a hearing later this month examining rising prescription drug prices. Sen. Chuck Grassley (R-IA), chairman of the Senate Finance Committee, and Sen. Ron Wyden (D-Ore.), ranking member of the committee, invited executives from AbbVie Inc., AstraZeneca PLC, Bristol-Myers Squibb Co.,…

Opioid Makers Paid Millions to Advocacy Groups

Nate Raymond  |  February 14, 2018

(Reuters)—Five opioid manufacturers, including OxyContin maker Purdue Pharma LP, have paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report said on Monday.1 The report, released by Sen. Claire McCaskill (D-Mo.), says groups who received the…

Republican Bill to Repeal Obamacare Teeters on Edge of Collapse

Susan Cornwell & Richard Cowan  |  September 25, 2017

WASHINGTON (Reuters)—The latest Republican effort to repeal former U.S. President Barack Obama’s signature healthcare law faced possible defeat this week as several senators in the party voiced concerns about the bill under consideration. The U.S. Senate is up against a Saturday deadline for deciding the fate of the 2010 Affordable Care Act, popularly known as…

Republican Bid to Gut Obamacare Fails in Senate

Yasmeen Abutaleb, Amanda Becker & David Morgan  |  July 28, 2017

WASHINGTON (Reuters)—A U.S. Senate led by Donald Trump’s fellow Republicans dealt the president a harsh blow on Friday, failing to move ahead with a major campaign promise to dismantle Obamacare as they fell one vote short of passing healthcare legislation. Three senators—John McCain (R-Az.), Susan Collins (R-ME) and Lisa Murkowski (R-Ala.)—joined Senate Democrats in the…

U.S. Senate Rejects Obamacare Repeal Again, Eyes a ‘Skinny’ Bill

Susan Cornwell and Yasmeen Abutaleb  |  July 27, 2017

WASHINGTON (Reuters)—Republicans in the U.S. Senate fell short again on Wednesday in their effort to end Obamacare, rejecting a measure to repeal large portions of President Barack Obama’s signature law that has provided health insurance to millions of Americans. But Republican Senate leaders, struggling to keep a seven-year-old promise to unravel the law, already were…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences